Half way into Gedea Biotech’s NEFERTITI clinical trial of pHyph antibiotic-free treatment of bacterial vaginosis
Lund, Sweden, September 8, 2021, 2021. Swedish women’s health company Gedea Biotech today announced that it has enrolled more than 50% of patients in the NEFERTITI…
Gedea Biotech granted US patent for its antibiotic-free treatment pHyph for women with vaginal fungal infections
Lund, Sweden, August 31, 2021. Swedish women’s health company Gedea Biotech today announced that it has been granted a patent (US 10,993,907) by the United States Patent and Trademark Office (USPTO) for thetreatment of fungal infections by the company’s compound glucono-δ-lactone (GDL). The patent…
Progress in the clinical trial for bacterial vaginosis
Now, 57 patients, patients have been enrolled in the NEFERTITI clinical trial. Thanks to persistent and inventive investigators, in Sweden and in…
Deltagare söks till NEFERTITI-studien
30 mars 2021 Bakteriell vaginos, den vanligaste orsaken till besvärande flytningar från underlivet hos kvinnor uppstår på grund av tillväxt av bakterier som ger en obalans av de naturligt förekommande bakterierna i vaginan. Tillståndet drabbar hundratusentals svenska kvinnor varje år och det…
First patient enrolled in Gedea Biotech’s NEFERTITI Clinical Trial of pHyph for antibiotic-free treatment of women with bacterial vaginosis
PRESS RELEASE 2021-02-01 Lund, Sweden, February 2nd, 2021. Swedish women’s health company Gedea Biotech today announced that it has enrolled the first patient in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The…
Gedea on Top 21 list
Labiotech.eu is the leading online media for the biotech industry in Europe. Gedea Biotech is the only Swedish company on Labiotech's annual list "The 21 European Biotech…
Gedea Biotech receives MHRA approval to initiate NEFERTITI Clinical Trial in the UK of pHyph for antibiotic-free treatment of women with bacterial vaginosis
Lund, Sweden, October 27, 2020. Gedea Biotech,today announces that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis…
Gedea Biotech gains ISO 13485: 2016 certification in preparation for CE marking and launch of antibiotic-free bacterial vaginosis treatment
Lund, Sweden, April 7, 2020. Gedea Biotech, an innovative women’s health company today received its certificate in accordance with ISO 13485: 2016…
82 % clinically cured in antibiotic-free treatment trial in women with bacterial vaginosis
PRESS RELEASE Lund, Sweden, March 11, 2020. Gedea Biotech, an innovative women’s health company today reported results from a clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). In this open-label, single-armed, multi-center study, 82% of…